Clinical trialNCT00003736CompletedInterventional

MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer

SponsorAbramson Cancer Center at Penn MedicineEnrollment200Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for breast cancer. Diagnostic procedures such as MRI may improve the ability to detect breast cancer. PURPOSE: Screening and diagnostic trial to study the effectiveness of MRI scans in women who are at high risk for developing breast cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Mitchell Schnall, PhD
Abramson Cancer Center at Penn Medicine
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

University of Toronto
Toronto, Ontario, Canada

United States

Ucsf Cancer Center and Cancer Research Institute
San Francisco, California, United States
Porter Adventist Hospital
Denver, Colorado, United States
University of Colorado Cancer Center
Denver, Colorado, United States
Hartford Hospital
Hartford, Connecticut, United States
Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Lineberger Comprehensive Cancer Center, Unc
Chapel Hill, North Carolina, United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States
Simmons Cancer Center - Dallas
Dallas, Texas, United States
Cancer Center at the University of Virginia
Charlottesville, Virginia, United States
University of Washington Medical Center
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Motexafin gadolinium →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 1999
Primary completion: 30 Jun 2002
Completion: 30 Jun 2002
Last update posted: 24 Sept 2019
Registered enrollment: 200
Registry id: NCT00003736

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.